Compass Therapeutics Inc.
NASDAQ:CMPX
Compass Therapeutics Inc.
EPS (Diluted)
Compass Therapeutics Inc.
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
EPS (Diluted)
$0
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
See Also
What is Compass Therapeutics Inc.'s EPS (Diluted)?
EPS (Diluted)
-0.3
USD
Based on the financial report for Sep 30, 2025, Compass Therapeutics Inc.'s EPS (Diluted) amounts to -0.3 USD.
What is Compass Therapeutics Inc.'s EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
12%
Over the last year, the EPS (Diluted) growth was 19%. The average annual EPS (Diluted) growth rates for Compass Therapeutics Inc. have been 12% over the past three years , 12% over the past five years .
